Eye Disease & Ophthalmology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

This study by the University of Wisconsin, Madison is creating a new retinal imaging dataset for people aged 50 and older, including those with and without Age-Related Macular Degeneration (AMD). The goal is to help develop AI tools that could detect AMD earlier and track its progression more accurately. For patients, this could mean better screening and monitoring options in the future, potentially leading to earlier treatment and improved vision outcomes.

The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia

In this Phase 4 trial completed in China, researchers tested eye drops containing Esculin and Digitalis glycosides to treat presbyopia, which is the normal age-related loss of near vision. The results could offer a new, non-surgical way to improve reading and close-up vision by helping the eye muscles work better. If these eye drops prove effective, they may provide a convenient option for people struggling with presbyopia.

Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia

This upcoming Phase 2 study plans to compare omega-3 supplements and eyelid cleansers as treatments for chalazia, a common eyelid condition in children. The hope is to find new, gentle treatments that improve eyelid health and reduce how often chalazia come back. This research could lead to easier and less invasive options for managing this uncomfortable condition in young patients.

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

This Phase 2 trial is testing a new eye drop medication called ZOC2017217 for adults with age-related cataracts. The study involves twice-daily use of the drops over 24 weeks and is recruiting participants in the United States. If successful, this treatment might offer a non-surgical way to improve vision or slow cataract progression, which could be important for people who are not ready or able to have cataract surgery.

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

This Phase 3 trial plans to compare a new drug called AVT29 with the current treatment Eylea HD for diabetic macular edema, an eye condition caused by diabetes that can lead to vision loss. While not yet recruiting, the study aims to find out if AVT29 works as well and is as safe as existing treatments. This could mean more treatment options and potentially better care for people living with this condition.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.